Advertisement
Kip 25

Primecap Odyssey Growth Stumbles

Primecap’s return trails the competition as well as the Standard & Poor’s 500-stock index, which returned 9.4%. What gives?

After posting a nearly flawless record since its 2004 inception, Primecap Odyssey Growth (symbol POGRX)—a member of the Kiplinger 25—stumbled over the past 12 months. Primecap’s 1.2% return trails the competition, which gained an average of 9.8% over the same period, and Standard & Poor’s 500-stock index, which returned 9.4%. The fund’s disappointing performance puts it behind 98% of funds that invest in large, growing firms. So, what happened?

Odyssey Growth lagged during the market’s recent downswing and subsequent upswing. Between mid September and late December 2018, the fund fell 23.8%—more than the 19.4% loss in the S&P 500. As the index recovered 16.6% in the first 16 weeks of 2019, the fund managed only a 14.8% return.

Advertisement - Article continues below

Primecap Odyssey tends to hold a healthy slug of assets in go-go health care shares and technology stocks, and that has proved a challenge. In particular, the fund has 32% of its assets invested in health care firms—mostly biotechnology companies. Health care and info tech shares have helped the fund’s performance over the long term, but 2018’s late-fall turbulence “was a forceful example of how quickly trends can reverse,” the firm said in an October report.

A recent drag on the fund has been Biogen (symbol BIIB, a top 25 holding. The biotech firm lost nearly one-third of its value in March, after it abandoned its Alz­heimer’s therapy, which was in late-stage trials. (Biogen still has a strong pipeline of treatments for other neurological diseases, and the stock has recovered a bit since then.)

Five managers divide the fund’s assets and run each part independently. They favor stocks in fast-growing firms that they think the market has underestimated. Cautiously optimistic, the managers expect growth in the U.S. economy and corporate earnings to slow. But in both cases, “solid growth should endure,” they say.

Though Odyssey Growth’s sector concentration can hobble returns at times, over the long haul, the strategy delivers. The fund’s 16.7% annualized return over the past decade beats the S&P 500 by an average of 1.5 percentage points per year and ranks among the top 23% of all large-growth funds.

Advertisement
Advertisement

Most Popular

11 Dividend-Paying Stocks You Should Think Twice About
dividend stocks

11 Dividend-Paying Stocks You Should Think Twice About

Dividend-paying stocks often can be a store of safety, but 2020 has been difficult on income equities. These 11 picks look like shaky plays despite th…
September 21, 2020
Medicare Basics: 11 Things You Need to Know
Medicare

Medicare Basics: 11 Things You Need to Know

There's Medicare Part A, Part B, Part D, medigap plans, Medicare Advantage plans and so on. We sort out the confusion about signing up for Medicare --…
September 16, 2020
How To Buy a Roth IRA When You Make Too Much To Qualify For One
Roth IRAs

How To Buy a Roth IRA When You Make Too Much To Qualify For One

With their tax-free growth and tax-free withdrawals, Roth IRAs are a great deal — if you qualify. If you don’t, well, there’s still a way to get into …
September 23, 2020

Recommended

10 of the Best Target-Date Fund Families
mutual funds

10 of the Best Target-Date Fund Families

The best target-date funds are a 'set it and forget it' approach to your retirement, but which fund family should you trust your money?
September 17, 2020
Best Bond Funds for Every Need
Investing for Income

Best Bond Funds for Every Need

In a changing market, it’s important to remember why we hold bonds in the first place.
September 15, 2020
How to Build a Bond Portfolio
Becoming an Investor

How to Build a Bond Portfolio

No single bond (or even bond fund) can do it all. We'll help you match your goals with appropriate fixed-income picks.
August 27, 2020
Time to Buy Japanese Shares?
Foreign Stocks & Emerging Markets

Time to Buy Japanese Shares?

In a weak global economy, T. Rowe Price Japan finds firms with healthy balance sheets.
August 27, 2020